Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections

Sam T. Donta, Peter Peduzzi, Alan S. Cross, Jerald Sadoff, Clair Haakenson, Stanley J. Cryz, Carol Kauffman, Suzanne Bradley, Glenn Gafford, Dan Elliston, Thomas R. Beam, Joseph F. John, Bruce Ribner, Robert Cantey, Carolyn H. Welsh, Richard T. Ellison, Edward J. Young, Richard J. Hamill, Howard Leaf, Roland ScheinMaury Mulligan, Caroline Johnson, Elias Abrutyn, J. Griffiss McLeod, Randa Hamadeh, Arn H. Eliasson, J. Bruce McClain, Gregory P. Melcher, J. William Kelly, W. Russel Byrne, Mark Wallace, Dennis Amundson, Barton Gumpert, David Slagle

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

To determine if passive immunization could decrease the incidence or severity of Klebsiella and Pseudomonas aeruginosa infections, patients admitted to intensive care units of 16 Department of Veterans Affairs and Department of Defense hospitals were randomized to receive either 100 mg/kg intravenous hyperimmune globulin (IVIG), derived from donors immunized with a 24-valent Klebsiella capsular polysaccharide plus an 8-valent P. aeruginosa O-polysaccharide-toxin A conjugate vaccine, or an albumin placebo. The overall incidence and severity of vaccine-specific Klebsiella plus Pseudomonas infections were not significantly different between the groups receiving albumin and IVIG. There was some evidence that IVIG may decrease the incidence (2.7% albumin vs. 1.2% IVIG) and severity (1.0% vs. 0.3%) of vaccine-specific Klebsiella infections, but these reductions were not statistically significant. The trial was stopped because it was statistically unlikely that IVIG would be protective against Pseudomonas infections at the dosage being used. Patients receiving IVIG had more adverse reactions (14.4% vs. 9.2%).

Original languageEnglish
Pages (from-to)537-543
Number of pages7
JournalJournal of Infectious Diseases
Volume174
Issue number3
StatePublished - Sep 22 1996
Externally publishedYes

Fingerprint

Pseudomonas Infections
Klebsiella
Globulins
Pseudomonas aeruginosa
Albumins
Incidence
Vaccines
Klebsiella Infections
Passive Immunization
Hospital Departments
Veterans
Polysaccharides
Intensive Care Units
Placebos
Tissue Donors

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Donta, S. T., Peduzzi, P., Cross, A. S., Sadoff, J., Haakenson, C., Cryz, S. J., ... Slagle, D. (1996). Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. Journal of Infectious Diseases, 174(3), 537-543.

Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. / Donta, Sam T.; Peduzzi, Peter; Cross, Alan S.; Sadoff, Jerald; Haakenson, Clair; Cryz, Stanley J.; Kauffman, Carol; Bradley, Suzanne; Gafford, Glenn; Elliston, Dan; Beam, Thomas R.; John, Joseph F.; Ribner, Bruce; Cantey, Robert; Welsh, Carolyn H.; Ellison, Richard T.; Young, Edward J.; Hamill, Richard J.; Leaf, Howard; Schein, Roland; Mulligan, Maury; Johnson, Caroline; Abrutyn, Elias; McLeod, J. Griffiss; Hamadeh, Randa; Eliasson, Arn H.; McClain, J. Bruce; Melcher, Gregory P.; Kelly, J. William; Byrne, W. Russel; Wallace, Mark; Amundson, Dennis; Gumpert, Barton; Slagle, David.

In: Journal of Infectious Diseases, Vol. 174, No. 3, 22.09.1996, p. 537-543.

Research output: Contribution to journalArticle

Donta, ST, Peduzzi, P, Cross, AS, Sadoff, J, Haakenson, C, Cryz, SJ, Kauffman, C, Bradley, S, Gafford, G, Elliston, D, Beam, TR, John, JF, Ribner, B, Cantey, R, Welsh, CH, Ellison, RT, Young, EJ, Hamill, RJ, Leaf, H, Schein, R, Mulligan, M, Johnson, C, Abrutyn, E, McLeod, JG, Hamadeh, R, Eliasson, AH, McClain, JB, Melcher, GP, Kelly, JW, Byrne, WR, Wallace, M, Amundson, D, Gumpert, B & Slagle, D 1996, 'Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections', Journal of Infectious Diseases, vol. 174, no. 3, pp. 537-543.
Donta ST, Peduzzi P, Cross AS, Sadoff J, Haakenson C, Cryz SJ et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. Journal of Infectious Diseases. 1996 Sep 22;174(3):537-543.
Donta, Sam T. ; Peduzzi, Peter ; Cross, Alan S. ; Sadoff, Jerald ; Haakenson, Clair ; Cryz, Stanley J. ; Kauffman, Carol ; Bradley, Suzanne ; Gafford, Glenn ; Elliston, Dan ; Beam, Thomas R. ; John, Joseph F. ; Ribner, Bruce ; Cantey, Robert ; Welsh, Carolyn H. ; Ellison, Richard T. ; Young, Edward J. ; Hamill, Richard J. ; Leaf, Howard ; Schein, Roland ; Mulligan, Maury ; Johnson, Caroline ; Abrutyn, Elias ; McLeod, J. Griffiss ; Hamadeh, Randa ; Eliasson, Arn H. ; McClain, J. Bruce ; Melcher, Gregory P. ; Kelly, J. William ; Byrne, W. Russel ; Wallace, Mark ; Amundson, Dennis ; Gumpert, Barton ; Slagle, David. / Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. In: Journal of Infectious Diseases. 1996 ; Vol. 174, No. 3. pp. 537-543.
@article{0e81d219d240497db5278139b7cc590b,
title = "Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections",
abstract = "To determine if passive immunization could decrease the incidence or severity of Klebsiella and Pseudomonas aeruginosa infections, patients admitted to intensive care units of 16 Department of Veterans Affairs and Department of Defense hospitals were randomized to receive either 100 mg/kg intravenous hyperimmune globulin (IVIG), derived from donors immunized with a 24-valent Klebsiella capsular polysaccharide plus an 8-valent P. aeruginosa O-polysaccharide-toxin A conjugate vaccine, or an albumin placebo. The overall incidence and severity of vaccine-specific Klebsiella plus Pseudomonas infections were not significantly different between the groups receiving albumin and IVIG. There was some evidence that IVIG may decrease the incidence (2.7{\%} albumin vs. 1.2{\%} IVIG) and severity (1.0{\%} vs. 0.3{\%}) of vaccine-specific Klebsiella infections, but these reductions were not statistically significant. The trial was stopped because it was statistically unlikely that IVIG would be protective against Pseudomonas infections at the dosage being used. Patients receiving IVIG had more adverse reactions (14.4{\%} vs. 9.2{\%}).",
author = "Donta, {Sam T.} and Peter Peduzzi and Cross, {Alan S.} and Jerald Sadoff and Clair Haakenson and Cryz, {Stanley J.} and Carol Kauffman and Suzanne Bradley and Glenn Gafford and Dan Elliston and Beam, {Thomas R.} and John, {Joseph F.} and Bruce Ribner and Robert Cantey and Welsh, {Carolyn H.} and Ellison, {Richard T.} and Young, {Edward J.} and Hamill, {Richard J.} and Howard Leaf and Roland Schein and Maury Mulligan and Caroline Johnson and Elias Abrutyn and McLeod, {J. Griffiss} and Randa Hamadeh and Eliasson, {Arn H.} and McClain, {J. Bruce} and Melcher, {Gregory P.} and Kelly, {J. William} and Byrne, {W. Russel} and Mark Wallace and Dennis Amundson and Barton Gumpert and David Slagle",
year = "1996",
month = "9",
day = "22",
language = "English",
volume = "174",
pages = "537--543",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections

AU - Donta, Sam T.

AU - Peduzzi, Peter

AU - Cross, Alan S.

AU - Sadoff, Jerald

AU - Haakenson, Clair

AU - Cryz, Stanley J.

AU - Kauffman, Carol

AU - Bradley, Suzanne

AU - Gafford, Glenn

AU - Elliston, Dan

AU - Beam, Thomas R.

AU - John, Joseph F.

AU - Ribner, Bruce

AU - Cantey, Robert

AU - Welsh, Carolyn H.

AU - Ellison, Richard T.

AU - Young, Edward J.

AU - Hamill, Richard J.

AU - Leaf, Howard

AU - Schein, Roland

AU - Mulligan, Maury

AU - Johnson, Caroline

AU - Abrutyn, Elias

AU - McLeod, J. Griffiss

AU - Hamadeh, Randa

AU - Eliasson, Arn H.

AU - McClain, J. Bruce

AU - Melcher, Gregory P.

AU - Kelly, J. William

AU - Byrne, W. Russel

AU - Wallace, Mark

AU - Amundson, Dennis

AU - Gumpert, Barton

AU - Slagle, David

PY - 1996/9/22

Y1 - 1996/9/22

N2 - To determine if passive immunization could decrease the incidence or severity of Klebsiella and Pseudomonas aeruginosa infections, patients admitted to intensive care units of 16 Department of Veterans Affairs and Department of Defense hospitals were randomized to receive either 100 mg/kg intravenous hyperimmune globulin (IVIG), derived from donors immunized with a 24-valent Klebsiella capsular polysaccharide plus an 8-valent P. aeruginosa O-polysaccharide-toxin A conjugate vaccine, or an albumin placebo. The overall incidence and severity of vaccine-specific Klebsiella plus Pseudomonas infections were not significantly different between the groups receiving albumin and IVIG. There was some evidence that IVIG may decrease the incidence (2.7% albumin vs. 1.2% IVIG) and severity (1.0% vs. 0.3%) of vaccine-specific Klebsiella infections, but these reductions were not statistically significant. The trial was stopped because it was statistically unlikely that IVIG would be protective against Pseudomonas infections at the dosage being used. Patients receiving IVIG had more adverse reactions (14.4% vs. 9.2%).

AB - To determine if passive immunization could decrease the incidence or severity of Klebsiella and Pseudomonas aeruginosa infections, patients admitted to intensive care units of 16 Department of Veterans Affairs and Department of Defense hospitals were randomized to receive either 100 mg/kg intravenous hyperimmune globulin (IVIG), derived from donors immunized with a 24-valent Klebsiella capsular polysaccharide plus an 8-valent P. aeruginosa O-polysaccharide-toxin A conjugate vaccine, or an albumin placebo. The overall incidence and severity of vaccine-specific Klebsiella plus Pseudomonas infections were not significantly different between the groups receiving albumin and IVIG. There was some evidence that IVIG may decrease the incidence (2.7% albumin vs. 1.2% IVIG) and severity (1.0% vs. 0.3%) of vaccine-specific Klebsiella infections, but these reductions were not statistically significant. The trial was stopped because it was statistically unlikely that IVIG would be protective against Pseudomonas infections at the dosage being used. Patients receiving IVIG had more adverse reactions (14.4% vs. 9.2%).

UR - http://www.scopus.com/inward/record.url?scp=9544243676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9544243676&partnerID=8YFLogxK

M3 - Article

C2 - 8769611

AN - SCOPUS:9544243676

VL - 174

SP - 537

EP - 543

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -